remoxipride

Remoxipride is a substituted benzamide antipsychotic that was previously marketed in Europe for the treatment of schizophrenia and acute mania. It is classified as an atypical antipsychotic by most sources, though some consider it typical. Remoxipride acts primarily as a selective antagonist at dopamine D2 and D3 receptors, with high selectivity for extrastriatal D2 receptors and significant affinity for sigma receptors. This pharmacological profile results in effective antipsychotic activity with a lower incidence of extrapyramidal side effects compared to older agents like haloperidol. The drug was initially launched by AstraZeneca (then Astra) under the brand name Roxiam in 1990 but was withdrawn from the market starting in 1993 due to cases of aplastic anemia (incidence approximately 1/10,000 patients). Remoxipride has been studied for both positive and negative symptoms of schizophrenia and showed efficacy similar to haloperidol but with improved tolerability[1][4][5][6][7].

Brand names

RoxiamRemide

Other names

remoxipride